Immunotherapy is now an effective treatment for lung cancer, supported by overall improvement of clinical outcomes and better tolerance. Common targets of immunotherapy agents include the programmed cell death protein 1 (PD-1) pathway and the cytotoxic T-lymphocyte associated protein-4 pathways (CTLA-4). However, a reinvigorated immune system may lead to disturbances in normal immune self-tolerance and, as a result, may induce off-target immune-related adverse events (irAEs). IrAEs can happen to any organ, such as lung, liver, skin, kidney, etc. For patients with lung cancer, immune-mediated lung injury occurs in about 3% to 5% of patients receiving immunotherapy, and the real-world incidence of this entity may be higher, especially now that immunotherapy is more commonly used.
The most common management strategy for irAEs is early prevention, early detection and early treatment. Most of irAEs are mild and can be managed through transient immunosuppression with corticosteroids, but high-grade events often require hospitalization and specialized treatment. Sometimes, discontinuing current therapy is necessary.
This Research Topic aims at providing a forum to update and discuss new discoveries in the field of pathogenesis and management of irAEs for patients with lung cancer, and learn their recent incidence. IrAEs discussed here refer to those caused by all types of immunotherapy methods, including mono and combination immunotherapy.
We welcome Original Research papers, Reviews, and Systematic Reviews on major trends and challenges in this field, including but not limited to:
- Recent incidence of irAEs of immunotherapy for lung cancer
- Pathogenesis of irAEs of immunotherapy for lung cancer
- Management of irAEs of immunotherapy for lung cancer
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Immunotherapy is now an effective treatment for lung cancer, supported by overall improvement of clinical outcomes and better tolerance. Common targets of immunotherapy agents include the programmed cell death protein 1 (PD-1) pathway and the cytotoxic T-lymphocyte associated protein-4 pathways (CTLA-4). However, a reinvigorated immune system may lead to disturbances in normal immune self-tolerance and, as a result, may induce off-target immune-related adverse events (irAEs). IrAEs can happen to any organ, such as lung, liver, skin, kidney, etc. For patients with lung cancer, immune-mediated lung injury occurs in about 3% to 5% of patients receiving immunotherapy, and the real-world incidence of this entity may be higher, especially now that immunotherapy is more commonly used.
The most common management strategy for irAEs is early prevention, early detection and early treatment. Most of irAEs are mild and can be managed through transient immunosuppression with corticosteroids, but high-grade events often require hospitalization and specialized treatment. Sometimes, discontinuing current therapy is necessary.
This Research Topic aims at providing a forum to update and discuss new discoveries in the field of pathogenesis and management of irAEs for patients with lung cancer, and learn their recent incidence. IrAEs discussed here refer to those caused by all types of immunotherapy methods, including mono and combination immunotherapy.
We welcome Original Research papers, Reviews, and Systematic Reviews on major trends and challenges in this field, including but not limited to:
- Recent incidence of irAEs of immunotherapy for lung cancer
- Pathogenesis of irAEs of immunotherapy for lung cancer
- Management of irAEs of immunotherapy for lung cancer
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
